Cargando…

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma

Histone deacetylase (HDAC) inhibitors, especially vorinostat, are currently under investigation as potential adjuncts in the treatment of neuroblastoma. The effect of vorinostat co-treatment on the development of resistance to other chemotherapeutic agents is unknown. In the present study, we treate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lautz, Timothy B., Jie, Chunfa, Clark, Sandra, Naiditch, Jessica A., Jafari, Nadereh, Qiu, Yi-Yong, Zheng, Xin, Chu, Fei, Madonna, Mary Beth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400660/ https://www.ncbi.nlm.nih.gov/pubmed/22829886 http://dx.doi.org/10.1371/journal.pone.0040816

Ejemplares similares

Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics
por: Zheng, X, et al.
Publicado: (2013)

Midkine Mediates Intercellular Crosstalk between Drug-Resistant and Drug-Sensitive Neuroblastoma Cells In Vitro and In Vivo
por: Chu, Fei, et al.
Publicado: (2013)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study
por: Skertich, Nicholas J., et al.
Publicado: (2022)

Biological Insight and Recent Advancement in the Treatment of Neuroblastoma
por: Rivera, Zoriamin, et al.
Publicado: (2023)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2020)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

Transactivation of bad by vorinostat-induced acetylated p53 enhances doxorubicin-induced cytotoxicity in cervical cancer cells
por: Lee, Sook-Jeong, et al.
Publicado: (2014)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

The effects of taxanes, vorinostat and doxorubicin on growth and proliferation of Echinococcus multilocularis metacestodes assessed with magnetic resonance imaging and simultaneous positron emission tomography
por: Huang, Xiangsheng, et al.
Publicado: (2018)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo
por: Chao, Min-Wu, et al.
Publicado: (2015)

Direct but No Transgenerational Effects of Decitabine and Vorinostat on Male Fertility
por: Kläver, Ruth, et al.
Publicado: (2015)

Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy
por: Zierfuss, Bettina, et al.
Publicado: (2020)

Methotrexate/tacrolimus/vorinostat: Lack of efficacy: case report
Publicado: (2022)

Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent
por: Xu, Qifu, et al.
Publicado: (2020)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells
por: Liao, Bo, et al.
Publicado: (2017)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

Time-dependent simvastatin administration enhances doxorubicin toxicity in neuroblastoma
por: Anderson, Colin C., et al.
Publicado: (2020)

Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer
por: Claerhout, Sofie, et al.
Publicado: (2011)

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
por: Sato, Akinori
Publicado: (2012)

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms
por: Silva, Gabriela, et al.
Publicado: (2013)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
por: Archin, NM, et al.
Publicado: (2012)

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Siegel, D S, et al.
Publicado: (2014)

Vorinostat enhances chemosensitivity to arsenic trioxide in K562 cell line
por: Li, Nainong, et al.
Publicado: (2015)

The HDAC Inhibitor Vorinostat Diminishes the In Vitro Metastatic Behavior of Osteosarcoma Cells
por: Mu, Xiaodong, et al.
Publicado: (2015)

Vorinostat protects against calcium oxalate-induced kidney injury in mice
por: WANG, LI, et al.
Publicado: (2015)

Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells
por: Kwak, Tae Won, et al.
Publicado: (2015)

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma
por: Gao, Minjie, et al.
Publicado: (2016)

Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer
por: Patel, Sukeshi, et al.
Publicado: (2016)

Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells
por: Ma, Xiaoli, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d1jtbl3k4749fv22aqh8umk8vj